Skip to main content

Table 1 Demographic and clinical characteristics of patients treated with immune checkpoint inhibitors

From: Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center

Characteristics All (n = 424) Newly diagnosed
CVD (n = 62)
No CVD (n = 362) P
Age (year) 62 ± 13.1 64.3 ± 10.2 62.1 ± 13.5 0.135
Sex     0.924
 Women 155 (36.6%) 23 (37.1%) 132 (36.5%)  
 Men 269 (63.4%) 39 (62.9%) 230 (63.5%)  
Race/Ethnicity     0.772
 White (non-Hispanic) 363 (85.6%) 55 (88.7%) 308 (85.0%)  
 Black (non-Hispanic) 32 (7.6%) 4 (6.5%) 28 (7.8%)  
 Hispanic 16 (3.8%) 1 (1.6%) 15 (4.2%)  
 Other 13 (3.1%) 2 (3.2%) 11 (3.1%)  
Primary cancer diagnosis    0.163
 Lung cancer 126 (29.7%) 20 (32.3%) 106 (29.3%)  
 Melanoma 72 (17.0%) 16 (25.8%) 56 (15.5%)  
 Kidney cancer 54 (12.7%) 7 (11.3%) 47 (13.0%)  
 Head and neck cancer 45 (10.6%) 6 (9.7%) 39 (10.8%)  
 Urothelial carcinoma 34 (8.0%) 6 (9.7%) 28 (7.7%)  
 Colorectal cancer 19 (4.5%) 4 (6.5%) 15 (4.1%)  
 Gastrointestinal cancers (other) 8 (1.9) 1 (1.6%) 7 (1.9%)  
 Hodgkin Lymphoma 7 (1.6%) 0 7 (1.9%)  
 Other cancer 59 (13.9%) 2 (3.2%) 57 (15.8%)  
Cardiovascular risk factors
 Hypertension 210 (49.5%) 36 (58.1%) 174 (48.1%) 0.146
 Ischemic heart disease 54 (12.7%) 9 (14.5%) 45 (12.4%) 0.649
 Hyperlipidemia 128 (30.2%) 24 (38.7%) 104 (28.7%) 0.114
 Diabetes 76 (17.9%) 14 (22.6%) 62 (17.1%) 0.301
Other cancer medications
 Doxorubicin 14 (3.3%) 3 (4.8%) 11 (3.0%) 0.464
 Carboplatin 114 (26.9%) 18 (29.0%) 96 (26.5%) 0.68
 Paclitaxel 88 (20.8%) 15 (24.2%) 73 (20.2%) 0.47
 Cyclophosphamide 4 (0.9%) 1 (1.6%) 3 (0.8%) 0.555
  1. Values were reported as mean ± standard deviation for continuous variables and frequency (%) for categorical variables